Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Yoon Cheah

Blood (2023) 142 (Supplement 1): 327.

https://doi.org/10.1182/blood-2023-179541

Published: 2023

Journal Articles

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Alessandra Tedeschi, Chan Yoon Cheah, Stephen S. Opat, Emma Verner, Laura Magnano, Narendranath Epperla, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Mary Ann Anderson

Blood (2023) 142 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2023-178841

Published: 2023

Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Jacob D. Soumerai, Masa Lasica, Stephen Opat, Chan Y. Cheah, Henry Chan, Emma Verner, Eva González Barca, Alessandra Tedeschi, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 9325–9327.

https://doi.org/10.1182/blood-2022-169664

Published: 2022

Journal Articles

Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies

Jiaoyan Lyu, Xiaopeng Ma, Ruiqi Huang, Liyun Zhao, Yiling Yu, Oscar Puig, Yang Liu, James Hilger

Blood (2022) 140 (Supplement 1): 3521–3522.

https://doi.org/10.1182/blood-2022-168474

Published: 2022

Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data

Chan Y. Cheah, Constantine S. Tam, Masa Lasica, Emma Verner, Peter J. Browett, Mary Ann Anderson, James Hilger, Yiqian Fang, David Simpson, Stephen Opat

Blood (2022) 140 (Supplement 1): 2321–2323.

https://doi.org/10.1182/blood-2022-169662

Published: 2022

Journal Articles

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Constantine S. Tam, Emma Verner, Masa Lasica, Alejandro Arbelaez, Peter J. Browett, Jacob D. Soumerai, James Hilger, Yiqian Fang, Jane Huang, David Simpson, Stephen Opat, Chan Yoon Y. Cheah

Blood (2021) 138 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2021-148451

Published: 2021

Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 4307.

https://doi.org/10.1182/blood-2019-124213

Published: 2019

Journal Articles

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Michael Wang, MD, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Javier Munoz, MD, Tycel J. Phillips, MD, Won-Seog Kim, MD PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Judith Trotman

Blood (2018) 132 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2018-99-117224

Published: 2018

Journal Articles

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Blood (2018) 132 (Supplement 1): 148.

https://doi.org/10.1182/blood-2018-99-117956

Published: 2018

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, FRACP, FRCPA, Judith Trotman, MBChB, FRACP, FRCPA, James Hilger, Xiaoping Zhang, Shibao Feng, PhD, Sunhee Ro, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 4057.

https://doi.org/10.1182/blood.V130.Suppl_1.4057.4057

Published: 2017

Journal Articles

Autoimmune Hemolytic Anemia and Hemolytic Transfusion Reactions in Two Patients with Waldenström Macroglobulinemia Treated with Combination BTK Inhibitor and PD-1 Inhibitor

Jad Othman, MBBS, Emma Verner, FRACP,FRCPA,MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Jane Huang, MD, Leo Lin, MD, James Hilger, Judith Trotman, FRACP, Robin E Gasiorowski

Blood (2017) 130 (Supplement 1): 5153.

https://doi.org/10.1182/blood.V130.Suppl_1.5153.5153

Published: 2017

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Constantine S. Tam, MBBS, MD FRACP, FRCPA, David Simpson, MBChB, Stephen Opat, FRACP, FRCPA, Won Seog Kim, MD, Ph. D., Michael Wang, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Patrick B Johnston, MD PhD, Javier Munoz, MD, Won-Sik Lee, MD, Paula Marlton, MBBS, David Gottlieb, MBBS, MD FRACP, FRCPA, Lai Wang, PhD, Jane Huang, MD, James Hilger, Ling Xue, PhD, Sunhee Ro, PhD, Judith Trotman, FRACP

Blood (2017) 130 (Supplement 1): 152.

https://doi.org/10.1182/blood.V130.Suppl_1.152.152

Published: 2017

Journal Articles

Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

Pier Luigi Zinzani, MD PhD, Max S Topp, MD, Sam LS Yuen, MBBS, FRCPA, FRACP, Chiara Rusconi, MD, Isabelle Fleury, MD MSc, FRCPC, Barbara Pro, MD, Giuseppe Gritti, MD, Michael Crump, MD, Wanling Hsu, MS, Elizabeth A. Punnoose, PhD, James Hilger, PhD, Mehrdad Mobasher, MD, Wolfgang Hiddermann, MD

Blood (2016) 128 (22): 617.

https://doi.org/10.1182/blood.V128.22.617.617

Published: 2016

Journal Articles

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, MD, Guillaume Cartron, MD PhD, Michael Hallek, Barbara F. Eichhorst, MD, Mark Kozloff, MD, Thomas A. Giever, Gerard Lozanski, MD, Elizabeth A. Punnoose, PhD, Jue Wang, James Hilger, PhD, Mehrdad Mobasher, MD, Gilles Salles, MD PhD

Blood (2016) 128 (22): 4393.

https://doi.org/10.1182/blood.V128.22.4393.4393

Published: 2016

Journal Articles

Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Gilles A. Salles, MD PhD, Thomas E. Boyd, MD, Franck Morschhauser, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD, Mark Kozloff, MD, Guillaume Cartron, MD PhD, Yan Li, James Hilger, Mehrdad Mobasher, Stephan Stilgenbauer, MD

Blood (2015) 126 (23): 829.

https://doi.org/10.1182/blood.V126.23.829.829

Published: 2015

Journal Articles

Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Gilles Andre Salles, Thomas E Boyd, MD, Franck Morschhauser, MD PhD, Clemens-Martin Wendtner, MD, James Lymp, PhD, James Hilger, Gregory Vosganian, Jane Huang, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 3337.

https://doi.org/10.1182/blood.V124.21.3337.3337

Published: 2014

NARROW

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Autoimmune Hemolytic Anemia and Hemolytic Transfusion Reactions in Two Patients with Waldenström Macroglobulinemia Treated with Combination BTK Inhibitor and PD-1 Inhibitor

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only